IP Verse

Medimmune Limited opposition analysis

COMPANY ANALYSIS

Latest patents of Medimmune Limited opposed by its competitors

Patent:
EP3218406
Grant Date:
Oct 2, 2024
Title:
Binding Molecules Specific For Cd73 And Uses Thereof
Oppositions:
2
Patent:
EP3157629
Grant Date:
Oct 5, 2022
Title:
Methods Of Cancer Treatment With Antagonists Against Pd-1 And Pd-L1 In Combination With Radiation Therapy
Oppositions:
1
Patent:
EP1942939
Grant Date:
Jul 7, 2021
Title:
Interleukin-13 Antibody Composition
Oppositions:
1
Patent:
EP3329018
Grant Date:
Mar 31, 2021
Title:
Methods For Treating Hepcidin-Mediated Disorders
Oppositions:
1
Patent:
EP2997036
Grant Date:
Mar 3, 2021
Title:
Purification Of Recombinantly Produced Polypeptides
Oppositions:
2
Patent:
EP2935268
Grant Date:
Feb 17, 2021
Title:
Pyrrolobenzodiazepines And Conjugates Thereof
Oppositions:
1
Patent:
EP2624859
Grant Date:
Mar 1, 2017
Title:
Factor Ii And Fibrinogen For Treatment Of Haemostatic Disorders
Oppositions:
1

Competitors of Medimmune Limited

STRAWMAN LIMITED

DERMIRA, INC.

GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

Want to track Medimmune Limited?

Feel free to send us a message here and we will get back to you